PMID: Summary Keywords Crohns disease, GLP, GLP-1, GLP-2 receptor agonist, IBD - inflammatory bowel disease, ulcerative colitis Citation Lee JJ, Bajgain P and Lightner AL (2026) GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity
Previous fungal research primarily focused on intracellular iron ion balance and redox regulation, predating the concept of ferroptosis
M.JungY
Ipamorelin Benefits and Uses So, what are some of the benefits and uses of ipamorelin
2023, doi: 10.1186/S12891-023-06259-3/PEER-REVIEW
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials